Common Stock, $0.001 par value
- Symbol
- GERN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
GERNNASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition On November 4, 2026, Geron Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and recent business highlights. A copy of the press release is attached as Exhibit 99.1.…
Press release in this filing
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights →meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.
GERON CORP · 8-K · Filed 2026-11-04
Exhibit 99.1 Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million range; lowered 2026 total operating expenses range to $220 million to $230 million Initiated gated commercial launch to expand RYTELO access to eligible LR-MDS patients in targeted European markets, with availability expected in Germany by end of year Ended Q3 2026 with cash, cash equivalents, restricted cash, and marketable securities of $339 million Company to host conference call and webcast today, November 4, 2026, at 8:00 a.m. ET FOSTER CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) - Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported financial results for the third quarter of 2026 and recent business highlights. “Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportu…
Open exhibit ↗